Phase 3 TRIUMPH-4 (NCT05931367) reported 28.7% body weight loss at 12 mg, 26.4% at 9 mg, vs 2.1% placebo at 68 weeks
Participants self-reported their ethnic backgrounds into categories such as White, Mixed, Asian or Asian British, Black or Black British, and Other ethnic groups, with the majority (~94%) identifying as White British
Participants receive comprehensive medical monitoring including regular laboratory testing, physical examinations, and close follow up that exceeds standard clinical care
He added that his family members were taking the Ousia medications too and that he was also fielding questions from them
Price it at your maintenance dose (typically 1.0 to 1.7mg), not the 0.25mg starter
The encouraging part is that new trials are unlocking more uses every year, and some clinics including ours are already helping patients with chronic pain and autoimmune disease access these medications, including in microdoses, even when they dont fit the traditional weight-loss criteria
